to instantly read 150+ free stories & 250-word summaries of all our stories

Warped priorities

Moving the needle: MIA for 20 years, Parkinson’s drug Apomorphine still evades Indians

Pharma companies Rusan and Britannia have launched a drug for Parkinson’s in India. But there are problems. One company can’t serve the hundreds of thousands of potential patients just yet. And the other lacks licence

16/03/19

Suraksha P

A sizeable Parkinson’s Disease population has been left in the lurch when it comes to procuring Apomorphine, a drug that acts rapidly to make patients mobile

Pharma companies blame the lack of neurologists and movement disorder specialists for patients not getting diagnosed and treated, which reduces their potential market

International pharmaceutical manufacturers see no incentive in entering India because of low purchasing power of Indian patients

Apomorphine has been available in Europe and the US for more than 15 years now. What’s keeping it out of the reach of Indians?

inspirationfeed-97068-unsplash-1-1920x1119.jpg

P hasn’t been able to walk properly and has suffered from tremors for over 12 years. He is shown getting a shot, and seconds later, he’s seen doing push-ups. Mumbai-based Nanavati Hospital’s video on its antidote to Parkinson’s Disease, uploaded earlier this month, seems too good to be true. In fact, neurologists all over the…

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story. Create a free account.

Or subscribe. Why? Let us explain.

Already Registered?

Related stories

More stories in /Healthcare & /Reportage

See all in Reportage & Technology

Want to read this story for free right now? Just

Read the full story instantly.
Just enter your email address.

Or subscribe. Why? Let us explain.

Or

By registering, you will be signed-up for an account which gives you access to a free story published once a week and archives of all our free stories. You will also receive a daily newsletter sent to your inbox. To unsubscribe, please visit the profile section in your account.

What you get

Access all free stories

100+ archived free stories, and all upcoming ones too.

Paid story summaries

Read an exclusive 200 word summary for all our paid stories.

Daily Newsletters

Our world-renowned emails, in your inbox, every day.

Or get full access to all our stories

About subscriptions

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

200+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs